Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617016 | 1.00 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL23388312 | 1.00 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29617020 | 1.00 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL25548228 | 0.89 | ADORA2A (0.45) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29617002 | 0.89 | ADORA2A (0.44) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL23388284 | 0.89 | ADORA2A (0.44) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29616994 | 0.89 | ADORA2A (0.44) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL23388364 | 0.87 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29616971 | 0.87 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL23388311 | 0.87 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022107044-A1 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-27 | — | — | WO | disclosed |